Molecule to Market: Inside the outsourcing space

The academic turned biopharma innovator

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with JaeB Kim, Managing Director at Samsung Biologics America.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with JaeB, covering:

• A year at one of the largest and fastest-growing CDMOs in the world.
• Growing a US presence within the thriving biopharma cluster in San Francisco Bay with ambitious plans for future expansion.
• The need for industry to ‘give’ in order to ‘take’ from innovation in academia, along with the pivotal role that collaboration has played during the pandemic.
• How Covid-19 has ‘tested the system’ from R&D to logistics and patient supply and how this will enable the sector to be better prepared for a more orchestrated response to future pandemics.

JaeB is a senior life sciences professional with 15 years of experience in biotech and biologics manufacturing. With an MBA and a PhD in Cancer Biology, he worked for PerkinElmer before joining global CDMO giant Samsung Biologics in 2020. JaeB is also an Adjunct Assistant Professor at Michigan State University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

From chemist to consultant

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Urvish Pandya, Managing Director at Allotrope Scientific Ltd.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Urvish, covering:

• The exponential growth of chemistry in India leading to the production of many fine Indian chemists all over the world.
• Honest advice on how to deal with being made redundant as a result of being caught in the crossfire of M&A in the outsourcing space.
• The role of guiding drug sponsors in finding the right CRO and CDMO match, then getting the best out of them as a partner.
• The need for more modular and flexible capabilities in later stages of the drug manufacturing process.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The unique general

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andrew Moore, General Manager at Pfizer CentreOne.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andrew, covering:

• The pride of being part of Pfizer in the last year and first-hand experience of working with CEO Albert Bourla.
• Lifelong leadership lessons learnt during eight years of military service in Iraq, where decisions cost lives.
• Being the only black guy in the room 99% of the time and the seriousness of being a black leader and the need to drive diversity for better business outcomes.
• Pushing yourself outside of your comfort zone by going from the corporate life to a ‘roll your sleeves up’ CEO at a university spin-out.

Andrew is an experienced healthcare leader and entrepreneur, who began his healthcare career in sales and marketing, including seven years at Pfizer. He has also held leadership roles Baxter, AmerisourceBergen and McKesson. Most recently Andrew was the CEO of AI start-up CogxVision before rejoining Pfizer. Prior to his professional career, Andrew served in the U.S. Army where he received multiple accolades, including the Bronze Star for his combat experience in Iraq Desert Storm.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The Stickability factor

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tom Moody, Vice President of Technology Development and Commercialisation at Almac.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• 20 years at Almac and being on a journey that has seen the company go from a few hundred staff to over 5500 people.
• The chemistry of today is not the chemistry of tomorrow, including the future impact of flow chemistry and the need to bring new technologies together.
• The importance of giving back to the community and inspiring the next generation of scientists.
• Reinventing yourself as a way to keep you on your toes

Prof. Tom Moody is the Vice President of Technology Development and Commercialisation at Almac Sciences. His work has earned him numerous accolades and he is co-author and author of over 60 publications and patents. He is a strategic leader and technical expert in chiral chemistry and biocatalysis with more than 20 years of extensive academic and industry experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Poacher turned gamekeeper, turned hybrid

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Bigelow President at xCell Strategic Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The transition from being on the big pharma sponsor side at Pfizer to being head of one of the world’s biggest CDMOs.
• The challenging of adding a development capability to well-oiled manufacturing infrastructure and way of working.
• They key buying criteria emerging pharma considers when choose a CDMO.
• Increasing consolidation and fragmentation in today’s outsourcing sector due to continued market growth and the explosion of new technologies.

Pete is a very well respect industry leader having spent over 25 years in the global pharmaceutical manufacturing space. He was at Wyeth and then Pfizer for the best part of 15 years before becoming the interim CEO and President of North American operations at Patheon. He since moved into management consulting before establishing his own firm called xCell in 2014.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The humble leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Ferguson, Chief Executive Officer at Medix Biochemica. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:

• The positive and negative impact of Covid-19 on the diagnostic sector. And the need for more spend on diagnostic sector moving forward.
• How his humble and grounded upbringing gave him an early respect for the strength of women and gender equality.
• Simply the importance of having fun, enjoying yourself and making a difference at work. Otherwise, what’s the point?
• The importance of creating visibility in a fragmented segment of the outsourcing space and then overlaying relevance to the buyer.

With around 25 years’ experience in the life science sector, Steve has worked for the likes of Lundbeck and Thermo Fisher before joining Medix Biochemica at the CEO. He is an expert in the pharma and diagnostic space and well-respected industry leader.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The understated, elite vaccine scientist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Archie Lovatt Life Sciences Biosafety Scientific Director at SGS.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Archie, covering:

• Being motivated by saving lives and seeing your contribution make a real impact on the world. Following your heart and not chasing the money.
• Seeing Covid-19 drugs developed in a parallel rather than sequential way, helping accelerate the process while not compromising on safety.
• Being acquired by SGS yet maintaining the entrepreneurial spirit to explore and innovate.
• The long term value to patients of now having more platform technologies and a greater operational infrastructure to deal with disease areas.

Archie is a vaccine, gene and cell therapy biosafety testing expert. He graduated with a PhD in molecular microbiology and has been in the industry for the best part of 30 years. During this time, he founded a CRO called Vitrology, which was then acquired by SGS in 2012 and has since served on the board as Scientific Operations Director. He was also voted into the top 100 most influential people in human medicine development and manufacture.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Creating a healthy culture

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeff Dill, CEO at Vynamic.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeff, covering:·    

• How to create, document, grow and internationally scale an incredible business culture.
• The shift towards greater industry collaboration as an important step for quicker drug approvals in the future.
• Servant leadership philosophy - to listen, be empathetic and enable.
• The drive and transparency needed to create a more diverse and inclusive workforce.

Jeff boasts over 20 years’ experience in the healthcare consulting world. Previously at Accenture, Jeff joined healthcare industry management consulting firm Vynamic in 2005, he has been there ever since and is now the CEO.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

40 at 40

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal Founder & Global President of ramarketing & usual host of the Molecule to Market podcast.
 
Raman has 20+ years of marketing and life science industry experience. Starting his career and setting up his business in the UK, Raman now resides stateside after relocating to the US to open an office in Boston. Raman previously worked for The Specials Laboratory and SCM Pharma before setting up and leading ramarketing globally.
 
In this special 40th episode, Raman is handing over the microphone and questions to his friend and returning guest Dan Stanton, Editor at Bioprocess International and Managing Editor at Xconomy. Your guest host is turning the tables and using his journalistic experience to present the show.

In this episode Dan and Raman chat about the evolution of ramarketing, going global and the cultural differences and risk adversity between UK and US business styles. They also discuss how a people-centric approach enabled ramarketing to flourish and offer up 7 timeless tips for handling PR. You will also hear how Raman’s early childhood experiences instilled his strong work ethic and took him from being a playground confectionary supplier to become a successful entrepreneur and global agency owner working across the life sciences and pharma sector.

Hear Raman discuss:
●     His early life and where his business ethic came from.
●     How his marketing expertise led him to become an ‘accidental agency owner’.
●     Why his playground entrepreneurial spirit defined him as a businessperson.
●     The value of developing a people-centric business & why you shouldn’t burn bridges in business.
●     7 timeless tips for working with journalists.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

From Pfizer to CDMO start-up

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gerry, covering:    

• The transition from two decades in Big Pharma to the entrepreneurial world of running a CDMO.
• Becoming known as the ‘lab down the hall’ for many clients with products in the clinical phase of development.
• The value of talking to people, networking and not being intimidated when starting out your own business.
• Consistently keeping your operational house in order in the face of increasing market demand.

Raman has taken great pleasure in getting to know fellow Bostonian Gerry, since moving to the states. An accountant by trade, Gerry worked for Pfizer for eighteen years in corporate and research & development roles, both globally and onsite. Since founding Velesco back in 2007, he has led the steady growth of the company’s operations and its most recent expansions. A phenomenal networker, Gerry enjoys connecting people and communicating with people within the sector.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!